Czech and Slovak Ophthalmology 212 Original article Ocular Surface Evaluation in Patients Treated With Prostaglandin Analogues Considering Preservative Agent Mlčáková Eva Mlčák Petr https://orcid.org/0000-0002-1832-7218 Karhanová Marta https://orcid.org/0000-0002-0879-3055 Langová Kateřina Marešová Klára https://orcid.org/0000-0002-9973-3145 3 10 2016 4 3

Purpose: The aim of this study was to evaluate the ocular surface in patients treated with prostaglandin analogues considering contained preservative agent. Methods: 60 patients with glaucoma or ocular hypertension treated with prostaglandin analogue monotherapy were enrolled in this observational study. 20 patients with glaucoma suspect or ocular hypertension without local or systemic glaucoma medication formed the control group. Demographic data and medical history were recorded for each participant. Patients filled in the Ocular surface disease index© (OSDI) questionnaire and underwent an ophthalmological examination including assessment of conjunctival hyperaemia according to Efron, tear film break up time (BUT) and fluorescein staining according to the Oxford grading scheme. Treated participants were divided into 3 groups according to the preservative contained in the currently used prostaglandin analogue: the preservative-free group (18 patients), the polyquaternium group (17 patients) and the benzalkonium chloride (BAK) group (25 patients). Results: The control group had significantly lower fluorescein staining than the preservative- free group (p=0.001), the polyquaternium group (p=0.007) and the BAK group (p=0.002). The conjunctival hyperaemia was significantly lower in the preservative-free group compared to the polyquaternium group (p=0.011). There was no significant difference among the other groups. The difference neither in the OSDI score nor in the BUT was statistically important. Conclusion: This study confirmed that the ocular surface is worse in patients treated with prostaglandin analogue monotherapy than in people without glaucoma medication. A significant difference among treated patients depending on a preservative agent was not proved.

 benzalkonium chloride glaucoma ocular surface disease preservatives prostaglandin analogues References Alm, A.: Latanoprost in the treatment of glaucoma. Clin Ophthalmol, 8; 2014: 1967–1985. Baudouin, C., Labbé, A., Liang, H. et al.: Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res, 29(4); 2010: 312–334. Baudouin, C., Renard, JP., Nordmann, JP. et al.: Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol, 23(1); 2013: 47–54. Batra, R., Tailor, R., Mohamed, S.: Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma, 23(1); 2014: 56–60. Bron, AJ., Evans, VE., Smith, JA.: Grading of corneal and conjunctival staining in context of other dry eye tests. Cornea, 22(7); 2003: 640–650. Cheng, JW., Xi, GL., Wei, RL. et al.: Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: a systematic review and meta-analysis. Curr Ther Res Clin Exp, 70(4); 2009: 335–350. Crichton, ACS., Vold, S., Williams, JM. et al.: Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hy- Cvenkel, B., Štunf, Š., Kirbiš, IS. et al.: Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma. Clin Ophthalmol, 9; 2015: 625–631. Databáze léků (online). Praha: Státní ústav pro kontrolu léčiv, 2015 (cit. 2016- 06-03). Dostupný z WWW: <http:// www.sukl.cz/modules/medication/search.php>. Efron, N.: Grading scales for contact lens complications. In Efron, N. (Ed), Contact lens complications, 3. ed. Edinburgh-Toronto, Elsevier/Saunders, 2012, p. 301-306. European glaucoma society: Terminology and guidelines for glaucoma, 4. ed, Savona, PubliComm, 2014, 195 p. Eyawo, O., Nachega, J., Lefebvre, P. et al.: Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol, 3; 2009: 447–456. Fechtner, RD., Godfrey, DG., Budenz, D. et al: Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea, 29(6); 2010: 618–621. Garcia-Feijoo, J., Sampaolesi, JR.: A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol, 6; 2012: 441–446. Hommer, A., Kimmich, F.: Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clin Ophthalmol, 5; 2011: 623–631. Honrubia, F., García-Sánchez, J., Polo, V. et al.: Conjunctival hyperemia with use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol, 93(3); 2009: 316–321. Karhanová, M., Mlčák, P., Fryšák, Z. et al.: Účinnost a snášenlivost tafluprostu 0,0015% bez konzervačních látek v léčbě glaukomu a oční hypertenze. Čes a Slov Oftal, 68(4); 2012: 150–155. Labbé, A., Pauly, A., Liang, H. et al.: Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther, 22(4); 2006: 267–278. Labbé, A., Terry, O., Brasnu, E. et al.: Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea, 31(9); 2012: 994–999. Leung, EW., Medeiros, FA., Weinreb, C.: Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol, 86; 2002: 418–423. Liehneová, I.: Farmakoterapie glaukomu. Čes a Slov Oftal, 66(4); 2010: 155– 158. Martone, G., Frezzotti, P., Tosi, GM. et al: An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol, 147; 2009: 725–35. Mathews, PM., Ramulu, PY., Friedman, DS. et al.: Evaluation of ocular surface disease in patients with glaucoma. Ophthalmology, 120(11); 2013: 2241–2248. Mlčák, P., Karhanová, M., Marešová, K.: Konzervativní léčba glaukomu. Prakt lékáren, 5(1); 2009: 22–25. Ocular surface disease index© (OSDI©) (online). Irvine, CA: Allergan, Inc., c2004 (cit. 2014-07-13). Dostupný z WWW: <http://www.thecenterforeyecareandoptical.com/UserFiles/OSDI_questionnare.pdf>. Paimela, T., Ryhänen, T., Kauppinen, A. et al.: The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Mol Vis, 18; 2012: 1189–1196. Pflugfelder, SC., Baudouin, C.: Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol, 5; 2011: 1575–1583. Pisella, PJ., Pouliquen, P., Baudouin, al.: Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study. Can J Ophthalmol, 50(2); 2015: 132–136. Rolando, M., Crider, JY., Kahook, MY.: Ophthalmic preservatives: focus on polyquaternium-1. Expert Opin Drug Deliv, 8(11); 2011: 1425–1438. Rossi, GCM., Pasinetti, GM., Scudeller, L. et al.: Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther, 29(4); 2013: 390–394. Rossi, GCM., Pasinetti, GM., Scudeller, L. et al.: Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol, 23(3); 2013: 296–302. Rossi, GCM., Tinelli, C., Pasinetti, GM. et al.: Dry eye syndrome – related quality of life in glaucoma patients. Eur J Ophthalmol, 19(4); 2009: 572–579. Rouland, JF., Traverso, CE., Stalmans, I. et al.: Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol, 97; 2013: 196–200. Růžičková, E.: Farmakoterapie glaukomu. In Rozsíval, P. (Ed), Trendy soudobé oftalmologie, sv. 4. Praha, Galén, 2007, s. 151–174. Růžičková, E.: Glaukom, Praha, Max - dorf, 2006, 95 s. Saade, CE., Lari, HB., Berezina, TL. et RN.: Prevalence of ocular surface disease in glaucoma patients. J Glaucoma, 17(5); 2008: 350–355. Šebesta, P.: Konzervativní terapie glaukomu. In Rozsíval, P. (Ed), Glaukom – vybrané kapitoly. Hradec Králové, Nucleus HK, 2008, s. 133–156. Toris, CB., Gabelt, BT., Kaufman, PL.: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol, 53(Suppl 1); 2008: S107–S120. Uusitalo, H., Chen, E., Pfeiffer, N. et al.: Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol, 88; 2010: 329–336. Výborný, P., Fučík, M., Rozsíval, P.: Glaukom. In Kuchynka, P. (Ed), Oční lékařství. Praha, Grada, 2007, s. 555–607. Výborný, P., Sičáková, S.: Denní dáv - ka benzalkonium chloridu – významné kritérium v léčbě glaukomu. Čes a Slov Oftal, 67(2); 2011: 63–66. Výborný, P., Sičáková, S., Veselá Flórová, Z.: Konzervační činidla – denní dávka benzalkonium chloridu v léčbě glaukomu z pohledu pacienta. Čes a Slov Oftal, 70(3); 2014: 95–97. Zimmerman, TJ., Hahn, SR., Gelb, L. et al.: The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther, 25(2); 2009: 145–152.